Results 61 to 70 of about 81,803 (228)

Diagnosis and Management of Polycythemia Vera Complicated by Cerebral Infarction and Subdural Hematoma: A Case Report

iLABMED, EarlyView.
A 70‐year‐old man with recurrent cerebral infarctions, a subdural hematoma, and atherosclerotic disease involving multiple extracranial vascular territories was subsequently diagnosed with polycythemia vera (PV). In patients with recurrent cerebrovascular events accompanied by otherwise unexplained persistent erythrocytosis, JAK2 mutation testing and ...
Hui Zhao, Jie Feng, Yu Jing, Wei Xie, Yingjiao Sha, Yanhong Gao   +5 more
wiley   +1 more source

BCR-ABL TKIs inhibit ABL kinase activity in human endothelial cells (EC).

, 2023
Human umbilical vein ECs were treated with the indicated BCR-ABL TKI or DMSO control at the Cmax concentration for 2 hours. A. Representative images of western blots for the ABL kinase target p-Y207 CRKL (top), total CRKL (middle) and β-actin loading ...
Yihua Wang (491766), Richard J. Travers (17419592), Jennifer L. Bays (17419595), Qing Lu (28914), Alanna Farrell (17335792), Alec Stepanian (17419598), Christopher Chen (367993), Iris Z. Jaffe (10995326)   +7 more
core   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [PDF]

, 2001
The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML). Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA- associated expression of the BCR-ABL peptide KQSSKALQR on class I-negative CIVIL ...
Lill, JR, Christmas, SE, Wang, LH, Macintyre, AR, Bourdon, A, Hill, SC, Rojas, J, Dodi, IA, Bonner, PLR, Aubert, G, Creaser, CS, Clark, RE, Rees, RC, Travers, PJ, Madrigal, JA   +14 more
core  

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms

Journal of Hematology & Oncology, 2016
Background Acquired imatinib (IM) resistance is frequently characterized by Bcr-Abl mutations that affect IM binding and kinase inhibition in patients with chronic myelogenous leukemia (CML).
Xiaoying Lan, Chong Zhao, Xin Chen, Peiquan Zhang, Dan Zang, Jinjie Wu, Jinghong Chen, Huidan Long, Li Yang, Hongbiao Huang, Bing Z. Carter, Xuejun Wang, Xianping Shi, Jinbao Liu   +13 more
doaj   +1 more source

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

BCR-ABL activity of TKI-resistant cells.

, 2023
Relative densitometric graphs of phosphorylation of CRKL, surrogate marker of BCR-ABL activity. IR—imatinib resistant, DR—dasatinib resistant. Phosphorylation levels were normalised to β-actin and related to the corresponding controls. Means and standard
Markéta Žáčková (15411811), Jana Březinová (15411805), Kamila Čermáková (15411799), Denisa Myslivcová (15411793), Tereza Macháčková-Lopotová (15411796), Hana Klamová (15411808), Ondřej Mitrovský (15411790), Adam Obr (541887), Šárka Ransdorfová (15411802)   +8 more
core   +1 more source

Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex

Oncotarget, 2017
Treatment of BCR-ABL+ human leukemia has been significantly improved by ABL tyrosine kinase inhibitors (TKIs), but they are not curative for most patients and relapses are frequently associated with BCR-ABL mutations, warranting new targets for improved treatments.
Chen, Min, Turhan, Ali G., Ding, Hongxia, Lin, Qingcong, Meng, Kun, Jiang, Xiaoyan   +5 more
openaire   +3 more sources

Small‐Molecule Kinase Inhibitors Modulating Circadian Rhythms

Medicinal Research Reviews, EarlyView.
ABSTRACT The circadian clock mechanism generates 24‐h rhythms crucial for regulating various physiological processes, and its dysregulation has been implicated in numerous diseases. In cells, the circadian clock operates through a transcriptional‐translational feedback loop, where phosphorylation plays a pivotal role in maintaining accurate circadian ...
Irene Castellino, Manuela Bartolini, Rudolf Andrys, Kamil Musilek   +3 more
wiley   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T., Tessa Holyoake, Michor Franziska, Michor, F., Holyoake Tessa, Clarkson Bayard, Foo, J., Mark W Drummond, Franziska Michor, Bayard Clarkson, Foo Jasmine, Drummond, M.W., Jasmine Foo, Clarkson, B., Drummond Mark W.   +14 more
core   +2 more sources